Polymeric Anti-HIV Therapeutics

被引：22

作者：

Danial, Maarten ^{[1
,2
,3
]}

Klok, Harm-Anton ^{[1
,2
]}

机构：

[1] Ecole Polytech Fed Lausanne, Inst Mat, CH-1015 Lausanne, Switzerland

[2] Inst Sci & Ingn Chim, Lab Polymeres, CH-1015 Lausanne, Switzerland

[3] CSIRO Mat Sci & Engn, Clayton, Vic 3168, Australia

来源：

MACROMOLECULAR BIOSCIENCE | 2015年 / 15卷 / 01期

关键词：

antiviral; HIV polymer therapeutics; inhibitor; microbicide; polyvalency; HUMAN-IMMUNODEFICIENCY-VIRUS; DEXTRAN SULFATE; DC-SIGN; ANTIRETROVIRAL THERAPY; RADICAL POLYMERIZATION; ENVELOPE GLYCOPROTEIN; IN-VITRO; SYNTHETIC PEPTIDE; CRYSTAL-STRUCTURE; DENDRITIC CELLS;

D O I：

10.1002/mabi.201400298

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The scope of this review is to highlight the application of polymer therapeutics in an effort to curb the transmission and infection of the human immunodeficiency virus (HIV). Following a description of the HIV life cycle, the use of approved antiretroviral drugs that inhibit critical steps in the HIV infection process is highlighted. After that, a comprehensive overview of the structure and inhibitory properties of polymeric anti-HIV therapeutic agents is presented. This overview will include inhibitors based on polysaccharides, synthetic polymers, dendritic polymers, polymer conjugates as well as polymeric DC-SIGN antagonists. The review will conclude with a section that discusses the applications of polymers and polymer conjugates as systemic and topical anti-HIV therapeutics.

引用

页码：9 / 35

页数：27

共 50 条

[1] Clinical Perspective of the Toxicology of Anti-HIV Therapeutics
Haubrich, Richard
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2010, 29 (01) : 122 - 122
[2] Regulatory issues of importance to developing anti-HIV therapeutics
Hastings, KL
TOXICOLOGIC PATHOLOGY, 1996, 24 (03) : 278 - 280
[3] Anti-HIV drugs for cancer therapeutics: back to the future?
Chow, Warren A.
Jiang, Chunling
Guan, Min
LANCET ONCOLOGY, 2009, 10 (01): : 61 - 71
[4] Engineering strategies of Anti-HIV antibody therapeutics in clinical development
Pihlstrom, Nicole
Bournazos, Stylianos
CURRENT OPINION IN HIV AND AIDS, 2023, 18 (04) : 184 - 190
[5] The role of phenotyping and replication 2 capacity in anti-HIV therapeutics
Baliga, CS
Sutton, RE
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2004, 6 (03) : 308 - 317
[6] Nonclinical Safety Assessment of Anti-HIV Therapeutics--A Regulatory Perspective
Myers, L. Peyton
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2010, 29 (01) : 121 - 121
[7] Nonclinical Safety Assessment of Anti-HIV Therapeutics--An Industry Perspective
Wolfgang, Grushenka H. I.
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2010, 29 (01) : 121 - 122
[8] Small molecules anti-HIV therapeutics targeting CXCR4
Grande, Fedora
Garofalo, Antonio
Neamati, Nouri
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (04) : 385 - 404
[9] Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles
Chiappetta, Diego A.
Hocht, Christian
Taira, Carlos
Sosnik, Alejandro
BIOMATERIALS, 2011, 32 (09) : 2379 - 2387
[10] Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances
Faria, Maria J.
Lopes, Carla M.
das Neves, Jose
Lucio, Marlene
PHARMACEUTICS, 2021, 13 (08)

← 1 2 3 4 5 →